Sean McClain ^UDM

Sean McClain, as the Founder & CEO of Absci, is steering the company in harnessing AI and synthetic biology for drug and target discovery. Absci's Integrated Drug Creation™ Platform is pivotal in identifying novel drug targets, discovering optimal biotherapeutic candidates, and generating efficient manufacturing cell lines. Their focus on developing Bionic Proteins™ and other novel drug designs sets them apart in the biotech and pharma industry. Absci's ambition is to translate innovative ideas into effective drugs, transforming the development of protein-based medicines.